Historique
Article de Périodique
Implementing buprenorphine treatment in community settings in Australia : experiences from the Buprenorphine Implementation Trial (2004)
(La mise en place des traitements à la buprénorphine dans les cabinets médicaux et les pharmacies en Australie : les expériences issues du BIT - Buprenorphine Implementation Trial)
Auteur(s) :
LINTZERIS, N. ;
RITTER, A. ;
PANJARI M. ;
CLARK, N. ;
KUTIN J. ;
BAMMER, G.
Année
2004
Page(s) :
S29-S41
Langue(s) :
Anglais
Refs biblio. :
22
Domaine :
Drogues illicites / Illicit drugs
Thésaurus mots-clés
BUPRENORPHINE
;
MEDECIN GENERALISTE
;
PHARMACIE
;
PROGRAMME
;
EVALUATION
;
METHADONE
;
COMPARAISON
Thésaurus géographique
AUSTRALIE
Résumé :
Buprenorphine was registered in Australia as a maintenance and detoxification agent for the management of opioid dependence in November, 2000, and became widely available in August 2001. This paper provides an overview of key developments in the introduction of buprenorphine treatment in Australia, with an emphasis upon the delivery of services in community-based (primary care) settings. A central study in this work was the Buprenorphine Implementation Trial (BIT), a randomized, controlled trial comparing buprenorphine and methadone maintenance treatment delivered under naturalistic conditions by specialist and community-based service providers (general practitioners and community pharmacist) in 139 subjects across nineteen treatment sites. In addition to conventional patient outcome measures (treatment retention, drug use, psychosocial functioning, and cost effectiveness), the BlT study also involved the development and evaluation of clinical guidelines, training programs for clinicians, and client literature, which are described here. Integration of treatment systems (methadone with buprenorphine, specialist and primary care programs) and factors thought to be important in the uptake of buprenorphine treatment in Australia since registration are discussed.
Affiliation :
National Addiction Centre, London, United Kingdom and the National Drug Alcohol Research Centre, Sydney, Australia
Cote :
Abonnement